One‐year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes
Authors:
- 20 November 2015
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (7) , 693-697
Abstract
Recombinant methionyl human leptin (metreleptin) therapy was shown to improve hyperglycaemia, dyslipidaemia and insulin sensitivity in patients with lipodystrophic syndromes, but its effects on insulin secretion remain controversial. We used dynamic intravenous (i.v.) clamp procedures to measure insulin secretion, adjusted to insulin sensitivity, at baseline and after 1 year of metreleptin therapy, in 16 consecutive patients with lipodystrophy, diabetes and leptin deficiency. Patients, with a mean [± standard error of the mean (s.e.m.)] age of 39.2 (±4) years, presented with familial partial lipodystrophy (n = 11, 10 women) or congenital generalized lipodystrophy (n = 5, four women). Their mean (± s.e.m.) BMI (23.9 ± 0.7 kg/m 2 ), glycated haemoglobin levels (8.5 ± 0.4%) and serum triglycerides levels (4.6 ± 0.9 mmol/l) significantly decreased within 1 month of metreleptin therapy, then remained stable. Insulin sensitivity (from hyperglycaemic or euglycaemic‐hyperinsulinaemic clamps, n = 4 and n = 12, respectively), insulin secretion during graded glucose infusion (n = 12), and acute insulin response to i.v. glucose adjusted to insulin sensitivity (disposition index, n = 12), significantly increased after 1 year of metreleptin therapy. The increase in disposition index was related to a decrease in percentage of total and trunk body fat. Metreleptin therapy improves not only insulin sensitivity, but also insulin secretion in patients with diabetes attributable to genetic lipodystrophies.Keywords
This publication has 20 references indexed in Scilit:
- What the Genetics of Lipodystrophy Can Teach Us About Insulin Resistance and DiabetesCurrent Diabetes Reports, 2013
- Comparison of Efficacy and Safety of Leptin Replacement Therapy in Moderately and Severely Hypoleptinemic Patients with Familial Partial Lipodystrophy of the Dunnigan VarietyThe Journal of Clinical Endocrinology & Metabolism, 2012
- Effects of leptin and adiponectin on pancreatic β-cell functionMetabolism, 2011
- Efficacy of leptin therapy in the different forms of human lipodystrophyDiabetologia, 2009
- Making insulin-deficient type 1 diabetic rodents thrive without insulinProceedings of the National Academy of Sciences, 2008
- Leptin therapy for partial lipodystrophy linked to a PPAR‐γ mutationClinical Endocrinology, 2007
- Metabolic Correction Induced by Leptin Replacement Treatment in Young Children With Berardinelli-Seip Congenital LipoatrophyPediatrics, 2007
- Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescenceCell Death & Differentiation, 2007
- Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophyMetabolism, 2007
- Leptin-Replacement Therapy for LipodystrophyNew England Journal of Medicine, 2002